GHRP-6

Where GHRP-6 comes from.

GHRP-6 is a synthetic six-amino-acid peptide first described in the published literature in 1984 by Cyril Bowers and colleagues at Tulane University, the same research group that later described GHRP-2. GHRP-6 is the foundational compound in the growth-hormone-releasing peptide (GHRP) class: the original published work establishing that synthetic peptides could release growth hormone through a pathway distinct from the GHRH receptor used GHRP-6 as the principal experimental tool. The compound predates the identification of the receptor on which it acts, which was later characterised in the 1990s and given the name growth-hormone secretagogue receptor (GHSR1a).

The peptide is built by Fmoc solid-phase peptide synthesis with two D-amino-acid substitutions (positions 2 and 5) that improve resistance to proteolytic degradation. After purification by reversed-phase HPLC the peptide is freeze-dried and sealed in vials. The freeze-dried form is stable at room temperature. The published literature uses GHRP-6 and growth-hormone-releasing peptide-6 interchangeably; the compound has no widely used trade name in research contexts.

PubMed lists more than 600 papers mentioning GHRP-6 as of 2026, more than any other single compound in the GHRP class. The published literature spans the original receptor-identification work of the 1980s and 1990s, animal pharmacology studies, ghrelin-receptor structural biology research, and a smaller body of human pilot studies. GHRP-6 is the compound most cited as the historical reference in the GHRP-class literature; later compounds in the class (GHRP-2, Hexarelin, Ipamorelin) are typically introduced in the published research with reference to GHRP-6.

What the research looks at.

GHRP-6 mechanism research established the foundational understanding of the growth-hormone secretagogue receptor (GHSR1a). Published structure-activity research in the 1990s used GHRP-6 as the principal tool to map the receptor binding pocket, and the compound was central to the work that culminated in the 1999 identification of the natural ligand ghrelin. Cell-culture binding studies measure GHRP-6 affinity at GHSR1a at potency lower than the later compound GHRP-2 but with substantial measurable activity.

A second strand of research has examined appetite-regulation pathways. GHSR1a receptors are expressed not only on anterior pituitary somatotrophs but also in hypothalamic regions involved in appetite regulation. Published animal studies measure the effects of GHRP-6 administration on neuronal activity in defined hypothalamic nuclei and on feeding-behaviour endpoints. The published literature describes the appetite-regulation effect as a notable pharmacological feature of GHRP-6 that is shared with the natural ghrelin ligand and is observed at lower intensity with selective GHSR1a-agonists such as Ipamorelin.

"GHRP-6 is the foundational research tool that established the growth-hormone-secretagogue receptor as a separate pharmacological target from the GHRH receptor."

A third line of research uses GHRP-6 in combination-research designs alongside GHRH-class compounds. Published animal studies report additive or synergistic effects on growth-hormone secretion when GHRP-6 is administered with native GHRH or with stabilised GHRH analogues, mirroring the combination-research designs used with GHRP-2. The literature describes these dual-receptor designs as producing pulsatile-secretion patterns that exceed single-receptor activation.

Where the published research does not go: there are no FDA or EMA approvals for GHRP-6 in any indication. Human pilot studies have been published but have not advanced to large randomised clinical trials. The compound is supplied as a research compound for laboratory research only.